Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Pruban opvejer risiciene ved behandling af akut, lokal fugtig dermatitis hos hunde, og anbefalede udstedelse af markedsføringstilladelse for Pruban.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Pruban exceeded the risks for the treatment of acute localised moist dermatitis in dogs, and recommended that Pruban be granted a market authorisation.